ALGS: Pevy and ASO-675 advance as synergistic HBV therapies, aiming to expand functional cure rates
The session highlighted novel HBV therapies targeting unmet needs, with pevy showing multi-pathway inhibition and superior potency in ongoing phase II trials. ASO-675, developed with Amoytop, advances rapidly in China and is set for combination studies with pevy to expand functional cure rates.Base…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.